COVID-19 immunisation set to get FDA EUA
Pharma giant AstraZeneca has submitted data to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its antibody duo AZD7442.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Pharma giant AstraZeneca has submitted data to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its antibody duo AZD7442.
Cell and Gene Therapy Processing?Personalised tumour treatments are expensive. This particularly applies to individual cancer therapies based on gene-modified T cells. Currently, they are produced manually or, at best, in a partially-automated process. In a collaboration project ProCell for Patient, two hospitals are currently working with Optima Pharma to develop an automated unit for the decentralised production of a CAR-T cell product in treatment centres.
The success of any adoptive cell therapy lies in how effectively and selectively engineered immune cells interact and kill cancer cells. Functional phenomics enables insights that can dramatically accelerate the development of next-gen cell therapies. evorion biotechnologies brings functional phenomics to pharma and biotech partners via exclusive access to a unique, proprietary pipeline for in-depth multi-modal analysis of thousands of cell-cell interactions at single-cell resolution.
BionTech SE, which has been very successful in the field of corona vaccines, is starting phase II tests with its colorectal cancer candidate BNT122.
This whitepaper provides insights into why it is critical to manage, optimize and streamline a supply chain to mitigate risks, such as those brought on by the COVID-19 pandemic.
Small-volume biopharmaceutical processes continue to grow as more biopharmaceutical, cell therapy and gene therapy companies develop products. A 2021 Association for Regenerative Medicine (ARM) report states that there are 1,085 cell, gene and tissue-based therapy developers worldwide. These companies are engaged in many small-volume (<10L) processes including early-stage drug development and autologous therapies.
Early phase clinical trials require expert support, often across many service areas and specialisms. Recruitment for trials can be complicated, with less flexibility and higher costs as you attempt to acquire top talent on a project-only basis. That’s why CROs are becoming increasingly indispensable. CROs offer fully formed, multi-skilled teams ready to go, who you can bring on board as and when needed.
A comparison of immune correlates of AstraZeneca’s Phase II/III COVID-19 vaccine trial shows what antibodiy titer is required to prevent symptomatic disease.
Graphene is an allotrope of carbon and the basic structural element of other allotropes such as graphite and carbon nanotubes. It’s one of the lightest materials known and the strongest compound discovered. With its exceptional mechanical stiffness, strength, elasticity, high surface area and outstanding electrical and thermal conductivity, Graphene is ideal for use in electronics, sensors, biomedical technologies, protective coatings, energy and composite applications.